Incyte announced Friday that the FDA issued a complete response letter for its PD-1 inhibitor Zynyz as a first-line treatment for non-small cell lung cancer.

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. | Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This ...

The U.S. Food and Drug Administration has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte (INCY) and MacroGenics (MGNX), due to issues found at a ...

The global pharma giant cut more than 400 jobs in the state last year, after investing at least $360 million in its local manufacturing operations.

It was supposed to be a “win-win”—a rare business deal that would provide a huge boost to both sides. Instead, it is turning into the acquisition that has hit big bumps, with layoffs, productivity ...

The Somerset-based pharmaceutical company announced June 20 that Matti Masanovich will take on the role, effective July 5. He succeeds Thomas Castellano, who left Catalent April 13 after 15 years with ...

Catalent trimmed its annual revenue and net income forecasts. The contract drug manufacturer said the cuts were due to operational challenges. Catalent said it continues to add new customers. It seems ...

May 8 (Reuters) - Catalent Inc (CTLT.N), opens new tab expects to cut by more than $400 million both its full-year revenue and core profit forecasts, the contract drug manufacturer said on Monday, ...

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up ...